Krystal Biotech (KRYS) PT Raised to $206 at Citi
Citi analyst Carly Kenselaar raised the price target on Krystal Biotech (NASDAQ: KRYS) to $206.00 (from $204.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)